Brookline Capital Markets Weighs in on Moderna Q2 Earnings

Key Points

• Brookline Capital Markets raised its Q2 2026 EPS estimate for Moderna to ($1.98) from ($2.14) and now models FY2027 near breakeven at ($0.08), signaling a modestly improved medium‑term earnings outlook despite continued negative 2026 consensus estimates.
• Moderna reported Q1 EPS of ($3.40), missing estimates, largely due to a roughly $950M litigation settlement, but revenue beat at $389M (up ~260% year‑over‑year), showing stronger top‑line momentum despite GAAP losses.
• Analyst and investor views remain mixed — the consensus average rating is "Reduce" with a $35.73 target — and insiders (including the president and a director) have executed notable stock sales, while institutional ownership sits around 75%.

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Brookline Capital Markets upped their Q2 2026 earnings estimates for shares of Moderna in a research note issued on Friday, May 1st. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($1.98) per share for the quarter, up from their prior forecast of ($2.14). The consensus estimate for Moderna's current full-year earnings is ($8.00) per share. Brookline Capital Markets also issued estimates for Moderna's Q3 2026 earnings at ($1.78) EPS, Q4 2026 earnings at ($2.31) EPS and FY2027 earnings at ($0.08) EPS.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million for the quarter, compared to analysts' expectations of $236.37 million. During the same quarter in the previous year, the firm posted ($2.52) EPS. The firm's revenue for the quarter was up 260.2% compared to the same quarter last year.

Several other research analysts have also commented on MRNA. Evercore set a $35.00 price objective on Moderna in a research report on Tuesday, February 17th. Leerink Partners reissued an "underperform" rating on shares of Moderna in a research report on Friday, January 30th. BMO Capital Markets raised Moderna from a "market perform" rating to a "buy" rating in a research report on Monday, January 12th. Morgan Stanley set a $33.00 price objective on Moderna in a research report on Friday. Finally, TD Cowen reissued a "hold" rating on shares of Moderna in a research report on Thursday, January 29th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Reduce" and an average target price of $35.73.

Moderna Trading Up 4.3%

NASDAQ:MRNA opened at $47.30 on Tuesday. The business's 50-day moving average is $51.84 and its two-hundred day moving average is $39.47. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. Moderna has a 12 month low of $22.28 and a 12 month high of $59.55. The firm has a market capitalization of $18.68 billion, a PE ratio of -5.80 and a beta of 1.05.

Hedge Funds Weigh In On Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the business. MUFG Securities EMEA plc acquired a new position in shares of Moderna during the second quarter worth approximately $28,000. Flagship Harbor Advisors LLC bought a new stake in Moderna during the fourth quarter worth approximately $31,000. Canton Hathaway LLC bought a new stake in Moderna during the first quarter worth approximately $31,000. Ameriflex Group Inc. raised its holdings in Moderna by 3,775.0% during the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company's stock worth $32,000 after purchasing an additional 1,208 shares in the last quarter. Finally, Cromwell Holdings LLC raised its holdings in Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company's stock worth $35,000 after purchasing an additional 341 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Abbas Hussain sold 5,682 shares of the business's stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the transaction, the director directly owned 12,066 shares in the company, valued at approximately $562,637.58. The trade was a 32.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 160,009 shares of the business's stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $48.84, for a total value of $7,814,839.56. Following the transaction, the president owned 1,457,427 shares of the company's stock, valued at approximately $71,180,734.68. This represents a 9.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 10.80% of the company's stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Q1 results and pipeline news drove renewed optimism: revenue topped expectations, management reiterated a 2026 growth framework (excluding the one‑time settlement), and Moderna highlighted EU approvals and late‑stage pipeline progress (including a U.S. PDUFA for its seasonal flu candidate). This momentum prompted several analysts to lift price targets. QuiverQuant: Price‑target/earnings analysis
• Positive Sentiment: Analysts note clinical and pipeline progress beyond COVID — RBC highlights advances in cancer vaccine and infectious‑disease programs, which support a longer‑term growth thesis if late‑stage readouts and approvals continue. Yahoo/RBC: Pipeline progress
• Positive Sentiment: Brookline Capital Markets modestly increased some forward estimates (Q2 and FY2027 tweaks), signalling that at least some sell‑side models see improved medium‑term earnings trajectory. MarketBeat: Brookline estimate updates
• Neutral Sentiment: Insider selling: Director Abbas Hussain sold 5,682 shares under a pre‑arranged Rule 10b5‑1 plan (disclosed filing). The trade reduces his stake but appears planned rather than opportunistic. InsiderTrades: Director sale
• Neutral Sentiment: Analyst/hedge‑fund positioning is mixed: some firms have increased exposure while others trimmed positions; consensus price targets remain below recent highs, reflecting divergent views on recovery timing. QuiverQuant: Institutional and analyst context
• Negative Sentiment: Near‑term EPS cuts from Brookline for Q3/Q4 (and other downward tweaks) highlight continued uncertainty about quarter‑to‑quarter profitability; consensus still expects multi‑year negative EPS for 2026. MarketBeat: Broker EPS revisions
• Negative Sentiment: The widened GAAP loss in Q1 was driven by a roughly $950M litigation settlement, which pushed EPS well below estimates and underscores legal/cost headwinds that temper near‑term profitability. Yahoo: Q1 loss & litigation impact

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.